Genomics Personalized Health

What Genomics Personalized Health does

Genomics Personalized Health (GPH) is a private, for-profit clinical genomics company founded circa 2019 and headquartered in Santa Monica, California. It delivers whole-genome sequencing (WGS) at 30x coverage through three go-to-market channels: direct-to-consumer individuals who purchase a one-time license to their genomic data, self-insured employers that offer WGS as an employee benefit on a subscription basis, and healthcare systems that access the platform through a Genomics-as-a-Service (GaaS) subscription model. The company positions itself at the intersection of consumer-facing genomics and enterprise-grade clinical infrastructure, supported by press mentions in outlets such as Forbes, Nature Biotechnology, and GenomeWeb.

The underlying technology is a clinical-grade sequencing pipeline operated out of CLIA-certified, CAP-accredited laboratories, with HIPAA and Privacy Shield compliance governing the handling of protected health information and cross-border data transfers. Sequencing output is delivered to consumers in a portable file format, enabling downstream re-analysis, while enterprise customers receive programmatic access to the sequencing platform via subscription. The company maintains an educational content partnership with the Icahn Institute for Genomics and Multiscale Biology, lending academic credibility to its consumer-facing materials.

Operationally, GPH is a small team of 11-50 employees with no disclosed funding rounds, no disclosed revenue, and no named enterprise customers. The website still routes commercial intent through contact forms and email marketing rather than a transactional checkout, consistent with an early-stage commercial posture. Its differentiation rests on a regulated laboratory stack and a multi-channel distribution strategy rather than any disclosed proprietary AI or computational biology capability, leaving its long-term defensibility dependent on regulatory credentials, data accumulation from sequenced customers, and the eventual conversion of B2B pipeline into recurring revenue.

Name

Genomics Personalized Health

Legal name

Genomics Personalized Health

Website

https://genomicspersonalizedhealth.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Genomics Personalized Health is a Santa Monica-based clinical genomics company offering 30x whole-genome sequencing to consumers, self-insured employers, and healthcare systems via CLIA/CAP-certified labs and a subscription-based GaaS model.

Ownership category

akta.pro rank

Product category

Genetic Testing Services

SIC

Services-Health Services (8000)

akta.pro primary industry

Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

akta.pro secondary industries

Population Genomics & Preventive Precision Health Programs (HLAAANAL), Hospital Shared Services, GPOs & System Support Organizations (HLAFAAAO)

Keywords

• Whole genome sequencing
• Genomic testing services
• Preventative wellness programs
• Precision medicine solutions
• Personal genomic data

Headquarters

HQ city

Santa Monica

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Whole Genome Sequencing Services: Consumer WGS service providing whole genome sequencing through CLIA/CAP certified US-based laboratories with physician-ordered tests and guided analysis and reporting.
2. Corporate/Enterprise Solutions: Complete concierge whole genome sequencing and analysis/reporting programs for self-insured employers including preventative wellness programs for employees.
3. Healthcare Systems - Genomics as a Service (GaaS): Patient population scale genomics solutions for healthcare systems implementing precision medicine programs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Genomics Personalized Health (GPH) is a consumer Whole Genome Sequencing (WGS) service provider that delivers 30x coverage of all 3.2 billion base pairs of the human genome through CLIA-certified and CAP-accredited U.S.-based laboratories. The company sells WGS services across three channels—direct-to-consumer individuals, self-insured employer preventative wellness programs, and healthcare systems implementing Genomics-as-a-Service (GaaS)—with physician-ordered testing, HIPAA-compliant cloud storage, and access to genetic counselors and pharmacists for guided interpretation.

Product overview

Genomics Personalized Health (GPH) operates as a consumer whole genome sequencing service provider offering a unified WGS service across three primary market channels: direct-to-consumer (individuals/families), Self-Insured Employers (corporate wellness programs), and Healthcare Systems (precision medicine programs). The core product is Whole Genome Sequencing (WGS) providing complete 30x coverage of all 3.2 billion base pairs of DNA. Supporting services include: HIPAA-compliant cloud storage for personal genomic data ownership and control, access to CLIA-certified and CAP-accredited U.S. laboratories, physician-ordered testing with genetic counselor and pharmacist access, and data access for partner analysis/reporting applications. The company emphasizes an open platform approach where users own and control their genomic data, which is made available in .txt file format for interoperability with partner applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Consumer Whole Genome Sequencing (WGS) Service Direct-to-consumer Whole Genome Sequencing service providing complete genomic data covering 100% of DNA (3.2 billion base pairs) with physician-ordered tests, HIPAA-compliant cloud storage of personal data, and ongoing access to genetic counselors and pharmacists for guided interpretation. Designed for individuals and families seeking personal genome sequencing for health risk awareness, carrier screening, drug response insights, and preventative health planning.
• Self-Insured Employer (SIE) Solutions Corporate preventative wellness and executive concierge programs for self-insured employers, empowering employees with their genomic data as a baseline for health, lifestyle, and wellness applications. Delivered through CLIA-certified and CAP-accredited U.S. laboratories with physician-ordered testing, HIPAA-compliant data storage in .txt format, and data ownership retained by the employee.
• Genomics as a Service (GaaS) for Healthcare Systems Patient population-scale genomic solutions enabling healthcare systems to implement precision medicine programs. Provides access to WGS laboratory infrastructure, analysis and reporting tools, HIPAA-compliant storage, and guided interpretation by healthcare professionals for system-wide genomic initiatives.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Icahn Institute for Genomics and Multi-scale Biology at Mount SinaiminorStrategic or Co-development PartnerReferenced as a video resource provider for genomics education. Video content from the institute is featured on the Genomics Personalized Health website for educational purposes regarding genomic analysis.

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Dante Labs: Dante Labs markets whole genome sequencing directly to consumers globally at aggressive price points and has expanded into health insights and pharmacogenomics. It is a direct competitor in DTC WGS, particularly on price and global reach.
• Helix: Helix operates a population genomics platform that combines clinical-grade sequencing with a partner app ecosystem and supports health system and population health programs. Its platform model and sequencing-plus-apps approach closely mirror GPH's open platform thesis.
• 23andMe: 23andMe is the largest direct-to-consumer genetic testing brand, historically offering genotyping and exome-based products, with WGS expansion. It is the dominant consumer-facing genomics brand and the primary benchmark GPH competes against in the DTC channel.
• Nebula Genomics: Nebula Genomics offers direct-to-consumer whole genome sequencing with privacy-focused data ownership and optional subscription-based access to genetic insights. It is a direct competitor to GPH's DTC WGS service with a similar open-data philosophy.
• Color Genomics: Color provides clinical-grade genetic testing with a strong focus on employer-sponsored and population health programs, including self-insured employer wellness offerings. It competes head-to-head with GPH in the SIE wellness channel and offers hereditary cancer and pharmacogenomics panels.

Broad incumbents

• Myriad Genetics: Myriad is an established clinical genomics company offering hereditary cancer, pharmacogenomic, and prenatal testing through healthcare providers. It competes with GPH in healthcare system channels and brings scale, reimbursement expertise, and brand recognition GPH lacks.
• Tempus: Tempus is a large, well-capitalized precision medicine company offering sequencing, clinical decision support, and AI-driven insights primarily for oncology and health systems. It represents the broader incumbent GPH competes against in healthcare system precision medicine deals.
• Ancestry: Ancestry operates the largest consumer genetic database globally with autosomal DNA microarray testing focused on genealogy. While not a direct WGS competitor, its massive DTC footprint and consumer genomics brand influence shape the market GPH targets.

Emerging players

• Sequencing.com: Sequencing.com offers direct-to-consumer DNA testing, genome data storage, and an app marketplace for genomic insights. It shares GPH's open-platform, user-owned data thesis and represents an emerging niche player in the same consumer WGS and data interpretation market.

Others

• Illumina: Illumina is the dominant sequencing instrument and reagent manufacturer whose NovaSeq technology underpins the entire WGS market. While not a direct service competitor, Illumina's pricing decisions, product roadmap, and consumer genomics spinoffs (e.g., Helix investment) materially affect GPH's economics and strategic options.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/genomics-personalized-health

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomics Personalized Health